Prognosis
Moderna Says Analysis Shows Covid Vaccine Immunity May Wane
- More breakthrough cases in people who received shots earlier
- Company describes new analysis of phase 3 trial in statement
This article is for subscribers only.
Moderna Inc. said that a new analysis of the late-stage clinical trial of its Covid-19 vaccine found a higher rate of breakthrough cases in people who got shots early in the study.
The analysis, detailed in a news release from Moderna on Wednesday, examined instances where immunized people in the company’s trial still contracted Covid-19 this summer, when the delta variant was surging.